NCT06894979 2026-03-12
Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma
Children's Oncology Group
Phase 1 Recruiting
Clinical Trials
5 trialsNCT05116254 2026-01-23
SADDRIN-1
The Netherlands Cancer Institute
Phase 1 Terminated
NCT03423628 2025-12-22
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
AstraZeneca
Phase 1 Recruiting
NCT04550104 2025-12-19
CONCORDE
University of Leeds
Phase 1 Recruiting
NCT05678010 2025-05-18
A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting